This Government Contract opportunity from Department Of Defense was posted on May 1, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
Oxygen Carrier Development for Biosynthetic Blood
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
This contract involves the research, design, and in vivo testing of synthetic molecules or particles capable of carrying oxygen with reversible binding and release under physiological conditions. The goal is to advance these biosynthetic oxygen carriers to a Technology Readiness Level (TRL) of 3 to 4, indicating early-stage development and validation. The contract aims to support innovative solutions for synthetic blood substitutes, which have potential applications in medical and defense fields. Issued by the Defense Advanced Research Projects Agency under the Department of Defense, the contract is categorized under NAICS code 325412, related to pharmaceutical preparation manufacturing. It is a subcontract opportunity announced on May 1, 2026, with a response deadline of May 19, 2026. The project focuses on advancing novel oxygen carrier technologies that can safely and effectively function within the human body, reflecting a strategic investment in biotechnological research for enhanced medical readiness.
General Info
Agency
NAICS
Place of Performance
VASet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Submission Closed
